Multidrug-resistant Gram-negative (MDRGN) Infection - Pipeline Insight, 2024

This “Multidrug-resistant Gram-negative (MDRGN) Infection- Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Multidrug-resistant Gram-negative (MDRGN) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Multidrug-resistant Gram-negative (MDRGN) Infection Understanding

Multidrug-resistant Gram-negative (MDRGN) Infection: Overview

The emergence of multidrug-resistant Gram-negative bacteria is a major concern in hospital settings in many parts of the world. Infections caused by these pathogens have become significantly challenging over the past two decades, particularly in the developing countries, and are associated with high morbidity and mortality rates as well as protracted hospital stay. Enterobacteriaceae including Klebsiella pneumoniae, Escherichia coli as well as Enterobacter spp. and non-lactose fermenting bacteria such as Pseudomonas aeruginosa and Acinetobacter spp. have been identified as major cause of multi-drug resistant bacterial infections. Infections caused by multi-drug resistant (MDR) Gram-negative bacteria have increased worldwide due to rampant use of broad-spectrum antibiotics. Besides MDR, at present, extensively drug-resistant (XDR), and pan-drug-resistant (PDR) strains of various Gram-negative organisms harboring various resistance mechanisms are encountered, posing significant challenges to microbiologists and clinicians. Paucity of development of new antibiotics have led researchers to revive older antibiotics, one of them being the polymyxins as a last resort to combat MDR-GNBs. Polymyxin B and polymyxin E(colistin) are available as approved medical formulations. Polymyxins act against Gram-negative bacteria such as Acinetobacter species, Pseudomonas aeruginosa, Klebsiella species, and Enterobacter species. The rise in the infections caused by MDR Gram-negative bacteria has led polymyxins to be the last-resort drugs. Multidrug-resistant Gram-negative bacilli (MDR-GNB) infections are a significant cause of morbidity and mortality in high-risk hematologic patients. Early diagnosis and management of antibiotic treatment in these patients is a challenge for physicians.

Multidrug-resistant Gram-negative (MDRGN) Infection- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multidrug-resistant Gram-negative (MDRGN) Infection pipeline landscape is provided which includes the disease overview and Multidrug-resistant Gram-negative (MDRGN) Infection treatment guidelines. The assessment part of the report embraces, in depth Multidrug-resistant Gram-negative (MDRGN) Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multidrug-resistant Gram-negative (MDRGN) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Multidrug-resistant Gram-negative (MDRGN) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Multidrug-resistant Gram-negative (MDRGN) Infection.

Multidrug-resistant Gram-negative (MDRGN) Infection Emerging Drugs Chapters

This segment of the Multidrug-resistant Gram-negative (MDRGN) Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Multidrug-resistant Gram-negative (MDRGN) Infection Emerging Drugs

ETX0462: Entasis Therapeutics Inc.ETX0462 is a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and biothreat pathogens including, P. aeruginosa, K. pneumoniae, S. maltophilia, E. coli, B. anthracis, Y. pestis, F. tularensis and Burkholderia spp. Similar to ß-lactam antibiotics, ETX0462 inhibits penicillin-binding proteins which are essential for bacterial cell wall biosynthesis, however, unlike ß-lactam antibiotics, ETX0462 is unaffected by ß-lactamase mediated resistance. ETX0462 is supported by CARB-X.

CF-370: Contra Fect CF-370 is an engineered lysin therapeutic candidate with potent activity against Pseudomonas aeruginosa (“P. aeruginosa”). As native lysins are typically unable to penetrate the outer membrane of gram-negative bacteria and consequently unable to work in vitro in human blood or in animal models, CF-370, represents the first lysin to bypass the outer membrane of P. aeruginosa and to enable potent activity in human serum. Furthermore, CF-370 has exhibited the hallmark in vitro features of the lysin class, including rapid and potent bactericidal activity, synergy with a broad range of standard of care agents and the eradication of biofilms inpreclinicalstudies.

Multidrug-resistant Gram-negative (MDRGN) Infection: Therapeutic Assessment

This segment of the report provides insights about the different Multidrug-resistant Gram-negative (MDRGN) Infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Multidrug-resistant Gram-negative (MDRGN) Infection

There are approx. 10+ key companies which are developing the therapies for Multidrug-resistant Gram-negative (MDRGN) Infection. The companies which have their Multidrug-resistant Gram-negative (MDRGN) Infection drug candidates in the most advanced stage, i.e. Phase III;Entasis Therapeutics Inc.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Multidrug-resistant Gram-negative (MDRGN) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Multidrug-resistant Gram-negative (MDRGN) Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Multidrug-resistant Gram-negative (MDRGN) Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multidrug-resistant Gram-negative (MDRGN) Infection drugs.

Multidrug-resistant Gram-negative (MDRGN) Infection Report Insights

• Multidrug-resistant Gram-negative (MDRGN) Infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Multidrug-resistant Gram-negative (MDRGN) Infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Multidrug-resistant Gram-negative (MDRGN) Infection drugs?
• How many Multidrug-resistant Gram-negative (MDRGN) Infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multidrug-resistant Gram-negative (MDRGN) Infection?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Multidrug-resistant Gram-negative (MDRGN) Infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Multidrug-resistant Gram-negative (MDRGN) Infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Entasis Therapeutics Inc.
• Super TransMedical
• Telum Therapeutics
• ContraFect
• Spero Therapeutics
• AGILeBiotics
• Bioharmony Therapeutics Inc
• Qpex Biopharma

Key Products

• ETX0462
• CF-370
• Gram-negative Lysins
• SPR206
• QPX9003

This product will be delivered within 2 business days.